United Kingdom Refractory Asthma Stratification Programme (RASP-UK)

Lead Research Organisation: Queen's University of Belfast
Department Name: Centre for Experimental Medicine

Abstract

Severe refractory asthma affects approximately 2% of the UK population, and has a total healthcare cost that is greater than that for all of the 10 - 15% of the population with mild/moderate asthma. International asthma guidelines advise the 'step-wise' increase of inhaled and oral corticosteroid treatment. However, for severe refractory asthma, the response to corticosteroids is often poor, and doctors often escalate to high dose inhaled or oral corticosteroids. Recent data suggests that this "one size fits all" approach to asthma treatment is poorly targeted. Our industry partners are developing new drugs for severe asthma, which will require a targeted approach in patients to identify who will respond.

We propose a two level approach:

(i) In some patients with severe asthma, a key clinical problem is non-adherence with corticosteroid therapy (non-adherence is where patients, intentionally or non-intentionally, do not take their prescribed treatment). This is common and is poorly recognised by physicians. It can result in patients being inappropriately labelled as having 'corticosteroid resistant' disease, and may cause patients to be escalated to more complex and expensive therapies, when they could be controlled on inhaled corticosteroid treatment. Assessing adherence objectively is a pre-requisite to optimising corticosteroid therapy. This programme will assess adherence using remote monitoring technologies and non-adherent patients will be assisted and managed within their clinical service.

(ii) Some severe asthma patients have inappropriate increases in corticosteroids in the absence of corticosteroid responsive inflammation, and this can cause significant harm due to treatment side-effects, without any treatment benefit. Our programme will validate a new way to optimise corticosteroid therapy using simple blood (blood eosinophil count, serum periostin level) and breath (exhaled nitric oxide) tests of corticosteroid response across the major United Kingdom Clinical Centres for Severe Asthma. We know that patients with low measures of these biomarkers have a low chance of having an asthma attack and we can safely reduce and optimise their corticosteroid treatment dose. This process of corticosteroid optimisation will identify two populations of severe asthma patients, with different patterns of lung inflammation, one with corticosteroid responsive disease with high eosinophils (these are inflammatory cells recruited to the lungs in asthma) which we call "T2-High"severe asthma and the other with corticosteroid unresponsive disease or "T2-Low" severe asthma. The T2-High group will be available for clinical trials of novel treatments which have already been developed by the Pharmaceutical Industry. We currently understand much less about the T2-Low group, and they will be studied intensively with measures of lung function and other tests including airway sampling using bronchoscopy (a telescope test in the lungs to get airway samples) . We will also follow them up for 12 months to see if they remain stable on their optimised corticosteroid dose and if the pattern of inflammation in the lungs changes over time. This strategy will help us identify new drug targets for this group, and these patients will then be able to enter trials of these novel treatments.

This programme is the first to take this type of stratification approach in severe refractory asthma, specifically to assess objectively adherence to current treatment, and then to test a way to optimise corticosteroid therapy. It will provide a world-leading step change in the care of patients with severe asthma. It will also enable a clinical trials programme to be expanded within the UK Severe Asthma Clinical Centres to allow the safe and targeted testing of new treatments.

Technical Summary

This programme will test a novel stratification strategy in severe asthma to improve clinical management and accelerate development of new therapies. There are 4 components:

1. Stratification by adherence to regular corticosteroid (CS) treatment. Objective identification of adherence to inhaled CS to (a) precisely identify truly CS unresponsive asthma phenotypes where new drugs are needed and (b) avoid inappropriate use of new complex therapies in patients who could be effectively controlled on inhaled CS.

2. Biomarker-based titration of CS therapy. In the absence of CS responsive inflammation, clinical response to CS is minimal and inappropriate CS escalation causes significant morbidity. In a 1-year, multi-centre randomised clinical trial, comparing biomarker titrated CS therapy to standard care, we will examine if individualised titration of CS dose using validated biomarkers (exhaled nitric oxide, blood eosinophil count and serum periostin) improves asthma outcome. This will also address another key question, specifically what proportion of patients with severe asthma develop typical eosinophilic airways inflammation associated with Type 2 cytokines (T2) on progressive CS withdrawal.

3. Identification of new therapeutic targets. Prior genetic/mechanistic studies of asthma have not stratified on inflammatory phenotype; thus, understanding of the pathophysiological mechanisms in which T2 inflammation is absent is poor. We will undertake deep-phenotyping of the stratified cohorts to identify important structure/function relationships.

4. Clinical trials programme for new T2 and non-T2 therapies. Stratification by inflammatory phenotype is central to novel target-specific therapies and biomarker-driven therapeutic options now exist for severe asthma. We will use our established clinical infrastructure to engage with pharmaceutical companies to facilitate access to stratified severe asthma patient populations for Phase 2 proof of concept studies.

Planned Impact

Patients - will benefit through the development of a logical approach to treatment, based on an innovative and objective biomarker-driven algorithm. Currently, treatment is based on a "blunderbuss" approach using high dose corticosteroids, without definite clinical effectiveness in any individual, but with predictable long term side-effects. This is unacceptable for the estimated 50% of severe asthma patients who do not respond to escalation of corticosteroid therapy. This programme will firstly assess adherence using simple home-based remote testing, and then secondly validate a simple clinical biomarker based algorithm, to optimise an individual's corticosteroid dose. This will improve patient outcomes, and many patients will have their corticosteroid burden reduced, with fewer long-term corticosteroid side-effects. Optimised patients with persistent severe asthma will then be able to take part in trials of novel targeted treatments. International treatment guidelines will adopt this strategy for severe asthma and Consortium members will disseminate data to support evidence-based management of severe asthma worldwide. Asthma UK is a Consortium partner, represents the patient's interests, and will lead on the communication of the outcomes to patients.

Clinicians - will be able to adopt outputs from this programme with an immediate and direct impact on clinical care. They will be able to identify poor adherence and engage in a transparent discussion with patients. The composite biomarker strategy (exhaled nitric oxide, blood eosinophil count and serum periostin) will be easily transferable into the clinic and will deliver more effective targeting of corticosteroids. These tests are simple, rapid and reproducible and will enable 'near patient' testing to make treatment decisions in severe asthma. Clinicians will avoid inappropriate use of novel biologics, and will be able to target them more appropriately.

Academics - will benefit from improved understanding of the mechanisms underlying different asthma endotypes. The POC studies clarifying the role for novel therapies directed against NOX4 and other novel molecules will be central to a stratified approach in severe asthma. We recognise that even with the new therapies in development, we are unlikely to have all the tools to treat all aspects of severe asthma and our stratification programme will facilitate the identification of new targets for the 'non-corticosteroid responsive' aspects of asthma, which will also in the longer term, provide substantial patient benefit.

Industry - Our industry partners have helped shape the programme, and strongly endorse the Consortium's stratification approach. Non-adherent patients often become adherent with corticosteroid therapy when closely supervised in clinical trials and as a result, trials are underpowered. Defining a 'gold standard' assessment of adherence will reduce trial size and/or increase power and save costs. Diagnostic companies in our Consortium will have the utility of the novel strategy assessed independently. Therapeutics companies will have access to cohorts of precisely phenotyped patients for the identification of novel targets, and for the testing of targeted new treatments. In the long term, it will provide a world-leading cohesive and stable clinical infrastructure, to design and deliver stratified proof of concept clinical trials, and thus speed up the drug development process.

Healthcare providers and policy makers - will have additional information relating to responsiveness and non-adherence to corticosteroid treatment and a strong evidence base for introducing new and expensive treatments for severe asthma. Targeting new treatments to responder populations will deliver economic benefit by avoiding inappropriate use of expensive novel therapies in patients who are either non-adherent with simpler less expensive treatments, or whose inflammatory phenotype is unresponsive to a new medication.

Organisations

Publications

10 25 50
 
Description Academy of Medical Sciences Summary Report March 2017. The Academy of Medical Sciences hosted a roundtable meeting to bring together key stakeholders to deliver stratified approaches to severe asthma in the NHS. Much of the proposed stratification process is aligned with the stratification pathway in RASP UK and RASP-UK will continue to provide important information in this patient group. Clinical Pathway prepared by Professor LG Heaney, Professor R Djukanovic and Professor ID Pavord.
Geographic Reach National 
Policy Influence Type Participation in a national consultation
URL https://acmedsci.ac.uk/file-download/20348674
 
Description BenRex
Amount £2,572,762 (GBP)
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start 06/2019 
End 06/2023
 
Description Boehringer Ingelheim Consortium Partnership
Amount £450,000 (GBP)
Organisation Boehringer Ingelheim 
Sector Private
Country Germany
Start 03/2017 
End 10/2020
 
Description European Commission H2020
Amount € 4,030,000 (EUR)
Funding ID 831434 
Organisation European Commission H2020 
Sector Public
Country Belgium
Start 06/2019 
End 06/2026
 
Description Leveraged Clinical Fellow
Amount £160,000 (GBP)
Organisation Queen's University Belfast 
Sector Academic/University
Country United Kingdom
Start 08/2016 
 
Description Leveraged PhD Studentship
Amount £48,000 (GBP)
Organisation Queen's University Belfast 
Sector Academic/University
Country United Kingdom
Start 10/2016 
End 09/2019
 
Description PhD Studentship
Amount € 108,000 (EUR)
Organisation Royal College of Surgeons in Ireland 
Sector Learned Society
Country Ireland
Start 09/2015 
End 08/2018
 
Description ADON ERS 3TR Collaboration 
Organisation AlveoliX AG
PI Contribution Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma.
Collaborator Contribution The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4.
Impact None as yet
Start Year 2019
 
Description ADON ERS 3TR Collaboration 
Organisation Amsterdam Medical Center
Country Netherlands 
Sector Hospitals 
PI Contribution Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma.
Collaborator Contribution The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4.
Impact None as yet
Start Year 2019
 
Description ADON ERS 3TR Collaboration 
Organisation Austrian Society of Pneumology
Country Austria 
Sector Learned Society 
PI Contribution Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma.
Collaborator Contribution The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4.
Impact None as yet
Start Year 2019
 
Description ADON ERS 3TR Collaboration 
Organisation Bispebjerg Hospital
Country Denmark 
Sector Academic/University 
PI Contribution Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma.
Collaborator Contribution The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4.
Impact None as yet
Start Year 2019
 
Description ADON ERS 3TR Collaboration 
Organisation European Lung Foundation
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma.
Collaborator Contribution The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4.
Impact None as yet
Start Year 2019
 
Description ADON ERS 3TR Collaboration 
Organisation European Respiratory Society (ERS)
Country European Union (EU) 
Sector Charity/Non Profit 
PI Contribution Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma.
Collaborator Contribution The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4.
Impact None as yet
Start Year 2019
 
Description ADON ERS 3TR Collaboration 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma.
Collaborator Contribution The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4.
Impact None as yet
Start Year 2019
 
Description ADON ERS 3TR Collaboration 
Organisation Karolinska Institute
Country Sweden 
Sector Academic/University 
PI Contribution Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma.
Collaborator Contribution The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4.
Impact None as yet
Start Year 2019
 
Description ADON ERS 3TR Collaboration 
Organisation Owlstone Ltd
Country United Kingdom 
Sector Private 
PI Contribution Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma.
Collaborator Contribution The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4.
Impact None as yet
Start Year 2019
 
Description ADON ERS 3TR Collaboration 
Organisation Philipp University of Marburg
Country Germany 
Sector Academic/University 
PI Contribution Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma.
Collaborator Contribution The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4.
Impact None as yet
Start Year 2019
 
Description ADON ERS 3TR Collaboration 
Organisation University Medical Center Gronigen
Department Rheumatology and Clinical Immunology (UMCG-R)
Country Netherlands 
Sector Hospitals 
PI Contribution Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma.
Collaborator Contribution The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4.
Impact None as yet
Start Year 2019
 
Description ADON ERS 3TR Collaboration 
Organisation University of Leicester
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma.
Collaborator Contribution The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4.
Impact None as yet
Start Year 2019
 
Description ADON ERS 3TR Collaboration 
Organisation University of Lodz
Country Poland 
Sector Academic/University 
PI Contribution Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma.
Collaborator Contribution The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4.
Impact None as yet
Start Year 2019
 
Description ADON ERS 3TR Collaboration 
Organisation University of Southampton
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma.
Collaborator Contribution The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4.
Impact None as yet
Start Year 2019
 
Description INTERREG CHITIN Award Cross-border Healthcare Intervention Trials in Ireland Network 
Organisation Belfast City Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution The value of the cross border element of this work is the sharing of clinical knowledge between two jurisdictions that are on a same island. These jurisdictions are separated by two different health systems which affect the access to care, the funding of health care and the background and training experiences of the clinical teams. By engaging in research using digital technology the project offers value to both health services by providing information for planning service design on both sides of the border. Hence, one of the key outcomes of the work will be to understand the how patients, clinicians and management systems view this technology. There is a shared interest in patient management and novel strategies to overcome the problem of non-adherence in asthma patients between the North and South that has resulted in a formal collaboration between Queens University Belfast and Royal College of Surgeons in Ireland. We are conducting the INCA_Sun protocol in these two sites. This would be the perfect opportunity to share lessons learnt and develop further projects. Professor Heaney has developed the FeNo suppression test and is the lead for the MRC RASP study in which this is a central feature. The FeNO suppression test is part of the INCA Sun project. Professor Heaney is recognised as a world authority in the severe asthma and is a central part of the INCA adherence project. . The method of assessing the interaction of adherence and the biomarker or airway inflammation, FeNO, developed by Professor Heaney represents an important concept in how to assess the interaction of biomarkers relevant to airway inflammation.
Collaborator Contribution This team of researchers in the Royal College of Surgeons in Ireland and Trinity College Dublin developed a small device that is attached to a Diskus inhaler. The device called INCA (Inhaler Compliance Assessment) electronically records the timing and inhaler technique when the diskus is used. Information on a microchip in the device allows both the doctor and the patient to track how the inhaler is being used. Drs Hayes (Cavan Monaghan RCSI Hospitals network) and Dr Counihan (Droghdea and Dundalk RCSI Hospitals network) are Consultant Chest Physicians. Each of these physicians has a close working relationship with the RCSI/INCA/Costello team, both through established informal clinical referral pathways and as clinicians who are part of the RCSI Hospitals network. Each of these clinicians has a dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. Hence, the appropriate support teams and environment are in place. We anticipate the trials nurses will work embedded within these services, as we have previously done at other centres. Drs McManus, Hayes and Moan in the Southern and Western Health & Social Care Trust Hospitals also have at their centres dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. They too have a close working relationship and referral pathway to Professor Heaney's clinic at the Belfast City Hospital.
Impact None as yet.
Start Year 2018
 
Description INTERREG CHITIN Award Cross-border Healthcare Intervention Trials in Ireland Network 
Organisation Daisy Hill Hospital
PI Contribution The value of the cross border element of this work is the sharing of clinical knowledge between two jurisdictions that are on a same island. These jurisdictions are separated by two different health systems which affect the access to care, the funding of health care and the background and training experiences of the clinical teams. By engaging in research using digital technology the project offers value to both health services by providing information for planning service design on both sides of the border. Hence, one of the key outcomes of the work will be to understand the how patients, clinicians and management systems view this technology. There is a shared interest in patient management and novel strategies to overcome the problem of non-adherence in asthma patients between the North and South that has resulted in a formal collaboration between Queens University Belfast and Royal College of Surgeons in Ireland. We are conducting the INCA_Sun protocol in these two sites. This would be the perfect opportunity to share lessons learnt and develop further projects. Professor Heaney has developed the FeNo suppression test and is the lead for the MRC RASP study in which this is a central feature. The FeNO suppression test is part of the INCA Sun project. Professor Heaney is recognised as a world authority in the severe asthma and is a central part of the INCA adherence project. . The method of assessing the interaction of adherence and the biomarker or airway inflammation, FeNO, developed by Professor Heaney represents an important concept in how to assess the interaction of biomarkers relevant to airway inflammation.
Collaborator Contribution This team of researchers in the Royal College of Surgeons in Ireland and Trinity College Dublin developed a small device that is attached to a Diskus inhaler. The device called INCA (Inhaler Compliance Assessment) electronically records the timing and inhaler technique when the diskus is used. Information on a microchip in the device allows both the doctor and the patient to track how the inhaler is being used. Drs Hayes (Cavan Monaghan RCSI Hospitals network) and Dr Counihan (Droghdea and Dundalk RCSI Hospitals network) are Consultant Chest Physicians. Each of these physicians has a close working relationship with the RCSI/INCA/Costello team, both through established informal clinical referral pathways and as clinicians who are part of the RCSI Hospitals network. Each of these clinicians has a dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. Hence, the appropriate support teams and environment are in place. We anticipate the trials nurses will work embedded within these services, as we have previously done at other centres. Drs McManus, Hayes and Moan in the Southern and Western Health & Social Care Trust Hospitals also have at their centres dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. They too have a close working relationship and referral pathway to Professor Heaney's clinic at the Belfast City Hospital.
Impact None as yet.
Start Year 2018
 
Description INTERREG CHITIN Award Cross-border Healthcare Intervention Trials in Ireland Network 
Organisation Letterkenny General Hospital
PI Contribution The value of the cross border element of this work is the sharing of clinical knowledge between two jurisdictions that are on a same island. These jurisdictions are separated by two different health systems which affect the access to care, the funding of health care and the background and training experiences of the clinical teams. By engaging in research using digital technology the project offers value to both health services by providing information for planning service design on both sides of the border. Hence, one of the key outcomes of the work will be to understand the how patients, clinicians and management systems view this technology. There is a shared interest in patient management and novel strategies to overcome the problem of non-adherence in asthma patients between the North and South that has resulted in a formal collaboration between Queens University Belfast and Royal College of Surgeons in Ireland. We are conducting the INCA_Sun protocol in these two sites. This would be the perfect opportunity to share lessons learnt and develop further projects. Professor Heaney has developed the FeNo suppression test and is the lead for the MRC RASP study in which this is a central feature. The FeNO suppression test is part of the INCA Sun project. Professor Heaney is recognised as a world authority in the severe asthma and is a central part of the INCA adherence project. . The method of assessing the interaction of adherence and the biomarker or airway inflammation, FeNO, developed by Professor Heaney represents an important concept in how to assess the interaction of biomarkers relevant to airway inflammation.
Collaborator Contribution This team of researchers in the Royal College of Surgeons in Ireland and Trinity College Dublin developed a small device that is attached to a Diskus inhaler. The device called INCA (Inhaler Compliance Assessment) electronically records the timing and inhaler technique when the diskus is used. Information on a microchip in the device allows both the doctor and the patient to track how the inhaler is being used. Drs Hayes (Cavan Monaghan RCSI Hospitals network) and Dr Counihan (Droghdea and Dundalk RCSI Hospitals network) are Consultant Chest Physicians. Each of these physicians has a close working relationship with the RCSI/INCA/Costello team, both through established informal clinical referral pathways and as clinicians who are part of the RCSI Hospitals network. Each of these clinicians has a dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. Hence, the appropriate support teams and environment are in place. We anticipate the trials nurses will work embedded within these services, as we have previously done at other centres. Drs McManus, Hayes and Moan in the Southern and Western Health & Social Care Trust Hospitals also have at their centres dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. They too have a close working relationship and referral pathway to Professor Heaney's clinic at the Belfast City Hospital.
Impact None as yet.
Start Year 2018
 
Description INTERREG CHITIN Award Cross-border Healthcare Intervention Trials in Ireland Network 
Organisation Royal College of Surgeons in Ireland
Country Ireland 
Sector Learned Society 
PI Contribution The value of the cross border element of this work is the sharing of clinical knowledge between two jurisdictions that are on a same island. These jurisdictions are separated by two different health systems which affect the access to care, the funding of health care and the background and training experiences of the clinical teams. By engaging in research using digital technology the project offers value to both health services by providing information for planning service design on both sides of the border. Hence, one of the key outcomes of the work will be to understand the how patients, clinicians and management systems view this technology. There is a shared interest in patient management and novel strategies to overcome the problem of non-adherence in asthma patients between the North and South that has resulted in a formal collaboration between Queens University Belfast and Royal College of Surgeons in Ireland. We are conducting the INCA_Sun protocol in these two sites. This would be the perfect opportunity to share lessons learnt and develop further projects. Professor Heaney has developed the FeNo suppression test and is the lead for the MRC RASP study in which this is a central feature. The FeNO suppression test is part of the INCA Sun project. Professor Heaney is recognised as a world authority in the severe asthma and is a central part of the INCA adherence project. . The method of assessing the interaction of adherence and the biomarker or airway inflammation, FeNO, developed by Professor Heaney represents an important concept in how to assess the interaction of biomarkers relevant to airway inflammation.
Collaborator Contribution This team of researchers in the Royal College of Surgeons in Ireland and Trinity College Dublin developed a small device that is attached to a Diskus inhaler. The device called INCA (Inhaler Compliance Assessment) electronically records the timing and inhaler technique when the diskus is used. Information on a microchip in the device allows both the doctor and the patient to track how the inhaler is being used. Drs Hayes (Cavan Monaghan RCSI Hospitals network) and Dr Counihan (Droghdea and Dundalk RCSI Hospitals network) are Consultant Chest Physicians. Each of these physicians has a close working relationship with the RCSI/INCA/Costello team, both through established informal clinical referral pathways and as clinicians who are part of the RCSI Hospitals network. Each of these clinicians has a dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. Hence, the appropriate support teams and environment are in place. We anticipate the trials nurses will work embedded within these services, as we have previously done at other centres. Drs McManus, Hayes and Moan in the Southern and Western Health & Social Care Trust Hospitals also have at their centres dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. They too have a close working relationship and referral pathway to Professor Heaney's clinic at the Belfast City Hospital.
Impact None as yet.
Start Year 2018
 
Description INTERREG CHITIN Award Cross-border Healthcare Intervention Trials in Ireland Network 
Organisation South West Acute Hospital
PI Contribution The value of the cross border element of this work is the sharing of clinical knowledge between two jurisdictions that are on a same island. These jurisdictions are separated by two different health systems which affect the access to care, the funding of health care and the background and training experiences of the clinical teams. By engaging in research using digital technology the project offers value to both health services by providing information for planning service design on both sides of the border. Hence, one of the key outcomes of the work will be to understand the how patients, clinicians and management systems view this technology. There is a shared interest in patient management and novel strategies to overcome the problem of non-adherence in asthma patients between the North and South that has resulted in a formal collaboration between Queens University Belfast and Royal College of Surgeons in Ireland. We are conducting the INCA_Sun protocol in these two sites. This would be the perfect opportunity to share lessons learnt and develop further projects. Professor Heaney has developed the FeNo suppression test and is the lead for the MRC RASP study in which this is a central feature. The FeNO suppression test is part of the INCA Sun project. Professor Heaney is recognised as a world authority in the severe asthma and is a central part of the INCA adherence project. . The method of assessing the interaction of adherence and the biomarker or airway inflammation, FeNO, developed by Professor Heaney represents an important concept in how to assess the interaction of biomarkers relevant to airway inflammation.
Collaborator Contribution This team of researchers in the Royal College of Surgeons in Ireland and Trinity College Dublin developed a small device that is attached to a Diskus inhaler. The device called INCA (Inhaler Compliance Assessment) electronically records the timing and inhaler technique when the diskus is used. Information on a microchip in the device allows both the doctor and the patient to track how the inhaler is being used. Drs Hayes (Cavan Monaghan RCSI Hospitals network) and Dr Counihan (Droghdea and Dundalk RCSI Hospitals network) are Consultant Chest Physicians. Each of these physicians has a close working relationship with the RCSI/INCA/Costello team, both through established informal clinical referral pathways and as clinicians who are part of the RCSI Hospitals network. Each of these clinicians has a dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. Hence, the appropriate support teams and environment are in place. We anticipate the trials nurses will work embedded within these services, as we have previously done at other centres. Drs McManus, Hayes and Moan in the Southern and Western Health & Social Care Trust Hospitals also have at their centres dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. They too have a close working relationship and referral pathway to Professor Heaney's clinic at the Belfast City Hospital.
Impact None as yet.
Start Year 2018
 
Description RASP UK Consortium 
Organisation Aerocrine
Country Sweden 
Sector Private 
PI Contribution Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers.
Collaborator Contribution The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED.
Impact Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015
Start Year 2015
 
Description RASP UK Consortium 
Organisation Amgen Inc
Country United States 
Sector Private 
PI Contribution Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers.
Collaborator Contribution The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED.
Impact Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015
Start Year 2015
 
Description RASP UK Consortium 
Organisation Asthma UK
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers.
Collaborator Contribution The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED.
Impact Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015
Start Year 2015
 
Description RASP UK Consortium 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers.
Collaborator Contribution The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED.
Impact Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015
Start Year 2015
 
Description RASP UK Consortium 
Organisation Boehringer Ingelheim
Country Germany 
Sector Private 
PI Contribution Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers.
Collaborator Contribution The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED.
Impact Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015
Start Year 2015
 
Description RASP UK Consortium 
Organisation Genentech, Inc
Country United States 
Sector Private 
PI Contribution Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers.
Collaborator Contribution The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED.
Impact Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015
Start Year 2015
 
Description RASP UK Consortium 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers.
Collaborator Contribution The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED.
Impact Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015
Start Year 2015
 
Description RASP UK Consortium 
Organisation Heart of England NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers.
Collaborator Contribution The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED.
Impact Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015
Start Year 2015
 
Description RASP UK Consortium 
Organisation Imperial College London
Department Imperial College Trust
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers.
Collaborator Contribution The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED.
Impact Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015
Start Year 2015
 
Description RASP UK Consortium 
Organisation Janssen Research & Development
Country Global 
Sector Private 
PI Contribution Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers.
Collaborator Contribution The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED.
Impact Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015
Start Year 2015
 
Description RASP UK Consortium 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers.
Collaborator Contribution The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED.
Impact Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015
Start Year 2015
 
Description RASP UK Consortium 
Organisation MedImmune
Country United States 
Sector Private 
PI Contribution Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers.
Collaborator Contribution The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED.
Impact Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015
Start Year 2015
 
Description RASP UK Consortium 
Organisation NHS Greater Glasgow and Clyde (NHSGGC)
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers.
Collaborator Contribution The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED.
Impact Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015
Start Year 2015
 
Description RASP UK Consortium 
Organisation Newcastle upon Tyne Hospitals NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers.
Collaborator Contribution The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED.
Impact Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015
Start Year 2015
 
Description RASP UK Consortium 
Organisation Niche.com, Inc.
PI Contribution Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers.
Collaborator Contribution The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED.
Impact Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015
Start Year 2015
 
Description RASP UK Consortium 
Organisation Royal Brompton Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers.
Collaborator Contribution The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED.
Impact Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015
Start Year 2015
 
Description RASP UK Consortium 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers.
Collaborator Contribution The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED.
Impact Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015
Start Year 2015
 
Description RASP UK Consortium 
Organisation University of Leicester
Country United Kingdom 
Sector Academic/University 
PI Contribution Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers.
Collaborator Contribution The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED.
Impact Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015
Start Year 2015
 
Description RASP UK Consortium 
Organisation University of Manchester
Country United Kingdom 
Sector Academic/University 
PI Contribution Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers.
Collaborator Contribution The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED.
Impact Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015
Start Year 2015
 
Description RASP UK Consortium 
Organisation University of Nottingham
Country United Kingdom 
Sector Academic/University 
PI Contribution Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers.
Collaborator Contribution The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED.
Impact Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015
Start Year 2015
 
Description RASP UK Consortium 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers.
Collaborator Contribution The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED.
Impact Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015
Start Year 2015
 
Description RASP UK Consortium 
Organisation University of Southampton
Country United Kingdom 
Sector Academic/University 
PI Contribution Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers.
Collaborator Contribution The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED.
Impact Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015
Start Year 2015
 
Description RASP UK Consortium 
Organisation Vitalograph
Country Global 
Sector Private 
PI Contribution Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers.
Collaborator Contribution The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED.
Impact Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015
Start Year 2015
 
Title A Cross-Sectional Study To Measure Cough In Severe Asthma 
Description This is an observational study designed to assess cough in asthmatics. Patients with severe asthma will be recruited as well as a control population with mild-moderate asthma. This study will use a combination of subjective and objective cough measures to assess the frequency of cough as well as its related morbidity in severe asthmatics. Comparisons will be made between T2-High and T2-Low patients defined using a composite biomarker profile (blood eosinophil count and FeNO) to assess the role of cough in each and these results will be compared to the transcriptomic and proteomic measurements in the RASP-UK where the same biomarker profiling is being used to define clinical sub-groups of severe asthma. This study aims to also improve characterisation of the T2-Low population and identify possible mechanisms for the pathophysiology of this group. 
Type Diagnostic Tool - Non-Imaging
Current Stage Of Development Initial development
Year Development Stage Completed 2017
Development Status Under active development/distribution
Impact None yet 
 
Title BenRex:Asthma Exacerbation Profile in patients on open label treatment with Benralizumab for severe eosinophilic asthma - an exploratory study 
Description The main focus of this project will be to understand the nature of asthma exacerbations that occur despite open label benralizumab therapy in severe eosinophilic asthma. In addition, the efficacy of benralizumab has been clearly demonstrated in placebo-controlled trials and now effectiveness and early predictors of response in the real world need to be considered. This pragmatic study would include people selected in a real world scenario treated with open label benralizumab injections for one year. Each exacerbation event where the patient is able to travel to the research site will be studied for the inflammatory and clinical profile and samples stored for microbiome analysis. This is a UK multicentre study in NHS Clinical Centres with a dedicated tertiary care difficult asthma service across a total of 15 sites. The study is funded by industry collaboration under Workstrand 4 of RASP UK Consortium Agreement. 
Type Therapeutic Intervention - Drug
Year Development Stage Completed 2017
Development Status Under active development/distribution
Clinical Trial? Yes
UKCRN/ISCTN Identifier N/A
Impact None yet. 
 
Title Exacerbation Profile In Patients On Mepolizumab For Severe Refractory Eosinophilic Asthma - An Exploratory Study 
Description Around 15% of the UK have asthma (1), of these, 10-20% have asthma which is difficult to control using current therapies and with high levels of morbidity resulting. These patients consume 50-60% (1,2) of the healthcare costs of asthma and as such, there is much interest in developing novel treatments for this group. The heterogeneity of inflammatory pathways underlying asthma are of great interest with development of biomarkers useful for phenotyping asthmatic patients and allowing more accurate assessment of their response to treatment. Traditionally, oral corticosteroids are used in eosinophilic, 'T2-high' asthmatic patients with good therapeutic effect, however, there are a group of T2-high patients who have refractory type-2 cytokine driven inflammation and airway eosinophilia despite oral corticosteroids. As such, there are several novel biological agents being engineered to block type 2 cytokine pathways including antagonists to IL5, IL13 and IL4. Mepolizumab is a humanised monoclonal antibody against IL5. Through a selective inhibition of eosinophilic inflammation, the agent reduces the number of eosinophils in sputum and blood, with important clinical outcomes such as a reduction of asthma exacerbations and a need for systemic glucocorticoids (3,4,5). The pre-licencing clinical trials have shown that selective inhibition of IL5 and presumptive removal of eosinophils reduces exacerbations by 50%, but while this is a significant reduction, patients with severe asthma continue to have severe exacerbations requiring systemic corticosteroid administration (3,4,5),. Therefore, the point of interest is eliciting the inflammatory phenotype and physiological characteristics of the remaining 50% of exacerbations and ascertaining whether systemic corticosteroids have a role when the IL-5 pathway has been blocked by Mepolizumab. Purpose/ Aim This is an observational study designed to phenotype exacerbations or worsening asthma control when participants are established on Mepolizumab. Key exploratory outcomes will be fall in lung function, change in symptom score and number of participants progressing to rescue oral corticosteroids during a clinical deterioration whilst on Mepolizumab. The hypothesis is as follows: In patients with severe refractory eosinophilic asthma, who have been established on mepolizumab: - increased asthma symptoms (exacerbations) will have no evidence of airway eosinophilia and will be clinically mild events associated with small reductions in lung function which may not require rescue oral corticosteroids. Outline plan of investigation This will be an open observational multi-centre, cohort study in participants with severe asthma (Global Initiative for Asthma (GINA) Steps 4 and 5 classification of asthma severity)(6) who are initiated on Mepolizumab in line with the NICE/SMC Clinical Guidelines. The study is exploratory and will assess deteriorations in asthma control to characterise the clinical severity of each exacerbation and the airway and systemic inflammatory phenotype associated with these events. Clinical assessment and management of each exacerbation will be in line with standard clinical guidelines (SIGN 153, British Guideline on the Management of Asthma, September 2016)(7,8). The study design incorporates a proportion of participants already established on Mepolizumab as well as participants who will be commenced on Mepolizumab on entry to the study. A baseline assessment of medical history, clinical examination, lung function and sputum/blood/urine for analysis will be undertaken along with quality of life questionnaires. Those newly started on Mepolizumab, will be assessed in a similar manner 3 months into the study. Subjects will be given an electronic peak flow recorder, symptoms diary and action plan for change in baseline symptoms. Participants will be asked to contact the clinic when they feel there has been a decline in asthma control and before they take rescue treatment, a clinic visit will be arranged. At this visit, all participants will have full medical assessment and clinical management based on detailed medical history, clinical findings and lung function measurement. Blood will be taken as part of this clinical assessment as outlined in the schedule of study procedures including biobanking of samples for whole blood gene expression, serum, plasma, sputum and urine. These samples will be stored for validation of additional biomarkers, aligned with the RASP-UK biomarker corticosteroid optimisation study. Number in study: This is a study will take place across 4 NHS sites within the UK, namely Belfast, Glasgow, Oxford and Leicester. The study design incorporates a proportion of participants already established on Mepolizumab and also participants starting on Mepolizumab, allowing recruitment of up to 150 participants in a 6 - 9 month window (all sites have large numbers of patients on the waiting list for the drug). Assuming a conservative 0.7 exacerbations per patient per year on mepolizumab (ca 160 events in an 18 month period) and a minimum rate of attendance of 65% this is 102 observed episodes. The study will be terminated when 100 clinical assessments at exacerbation in total have been completed across all sites for participants on Mepolizumab prior to initiation of rescue treatment. The expected duration of study per participant is 24 months. Feasibility assessment: This study will be presented for Ethical approval on the 7th September 2017, after which it will be submitted for Research and Development approval. The aim is to have commenced the study before Christmas 2017. As per the above outline, we hope to have recruited 150 patients in a 6-9 month window and to have the anticipated number of exacerbations by Christmas 2019. The anticipated time of study is from August 2017 until August 2020. 
Type Management of Diseases and Conditions
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2017
Development Status Under active development/distribution
Clinical Trial? Yes
UKCRN/ISCTN Identifier Not applicable
Impact None yet. 
URL https://clinicaltrials.gov/show/NCT03324230
 
Title Inhaler Compliance Assessment (Asthma) INCA SUN 
Description A prospective randomised multicentre study to optimise the management of symptomatically uncontrolled asthma patients comparing two management approaches one in which technology that objectively records medication use and aligns this with the patient's clinical course is compared to usual care, i.e. no technology.This is a prospective randomised, multicentre study of patients with severe asthma comparing two different educational interventions. One arm will use electronic recorded and integrated information from the INCA device, PEFR and environmental data. In the second, current best practice comprising, adherence optimisation, asthma education, written action plans and inhaler training will be performed. The primary endpoint will be maintenance of adherence to salmeterol/fluticasone as judged by comparing the actual rate of adherence between active and control arms over the last 12 weeks of the study. The cost effectiveness and clinical utility will be secondary endpoints. 
Type Therapeutic Intervention - Medical Devices
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2016
Development Status Under active development/distribution
Clinical Trial? Yes
Impact N/A 
URL http://www.incadevice.com/inca-sun-study/
 
Title Persistence Of Inflammation And Study Of T2 Pathways Following Inhibition Of Interleukin-5 With Mepolizumab In Severe Eosinophilic Asthma - MAPLE 
Description The aim of the project is to study the persistence of inflammation after addition of an interleukin-5 blocker in severe eosinophilic asthma as a study of untreated pathways in these patients. Using two week s of high dose prednisolone versus placebo in a crossover design after 12 weeks of mepolizumab therapy will allow an understanding of the pathways that remain steroid responsive following IL-5 suppression. Primary Objective:Change in airway inflammation following oral corticosteroid versus placebo. Secondary Objective:Airway inflammation while on mepolizumab in a stable state of asthma. Endpoint:This is an exploratory study with no single end point. Hypothesis:Despite reduction of eosinophils by blocking the IL-5 pathway with mepolizumab, inflammation can persist due to other inflammatory corticosteroid responsive pathways. Patients due to receive mepolizumab in NHS clinics for severe eosinophilic asthma (Global Initiative for Asthma (GINA) Step 4/5 classification of asthma severity), initiated in line with the NICE/SMC Clinical Guidelines18,19 and are not on oral corticosteroids for the past 4 weeks [high dose or maintenance] will have baseline assessments performed as in the Study Schedule. At least 12 weeks after mepolizumab treatment, provided there has been no intake of systemic corticosteroids for =4 weeks, patients will be randomised to receive oral prednisolone 0.5 mg/kg [rounded to the nearest multiple of 5] or matching placebo for 14 days in a cross-over design, with a minimum 4 week gap between treatments. Baseline exhaled nitric oxide, blood, urine, sputum, breath [sub-study] and nasal epithelial samples will be collected and the same assessments will be repeated at the start and end of the steroid/placebo trial and analysed to compare the difference with additional corticosteroid or placebo. This is a UK multicentre study in NHS Clinical Centres with a dedicated tertiary care difficult asthma service which includes, but is not limited to, the following Centres: • Gartnavel Hospital Glasgow, Greater Glasgow & Clyde Health Board • Belfast Health & Social Care Trust • Oxford University Hospitals NHS Trust • Leicester University and Glenfield Hospital 
Type Therapeutic Intervention - Drug
Current Stage Of Development Wide-scale adoption
Year Development Stage Completed 2018
Development Status Under active development/distribution
Clinical Trial? Yes
Impact None yet. 
URL https://clinicaltrials.gov/show/NCT03610685
 
Title RASP Bronchoscopy Study 
Description This is a multi-centre bronchoscopy study designed to investigate the underlying molecular pathways driving severe asthma. This improved mechanistic understanding is important for the identification and effective targeting of novel therapeutic targets in severe asthma. The primary endpoint is the gene expression levels in airway biopsies and brushes from corticosteroid-optimised patients with severe asthma. The study received ethical approval in July 2016 and recruitment of patients to the study is underway in 5 study sites. 
Type Management of Diseases and Conditions
Current Stage Of Development Initial development
Year Development Stage Completed 2016
Development Status Under active development/distribution
Impact Not applicable at this stage 
 
Title RASP UK Biomarker Study 
Description Difficult to treat asthma affects up to 20% of patients with asthma in the UK despite currently available therapies and is associated with significant healthcare cost. Treatment guidelines advise the 'step wise' increase of corticosteroids but the response is often poor as this "one size fits all" approach does not benefit all patients. Characterising a patient's response to treatment will help our understanding of non-response and will aid development of new drugs for severe asthma. The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry. Our primary focus is to target corticosteroid treatments more effectively and to understand why some patients do not respond to corticosteroids. Our industry partners are developing new treatments for severe asthma that will be tested in these patients and asthma 'biomarkers' will be identified to predict response to these new therapies. Two approaches will initially be used to differentiate between patients who respond and do not respond to corticosteroid treatment, as follows: In some patients with difficult to treat asthma, the problem is non-adherence, whereby patients, intentionally or non-intentionally, do not take their prescribed corticosteroid treatment. This is common and is poorly recognised by doctors. This can result in patients being inappropriately labelled as having 'corticosteroid resistant' disease. Assessing adherence objectively is a pre-requisite to optimising corticosteroid therapy. The Consortium programme will assess adherence using remote monitoring technologies and non-adherent patients will be assisted and managed within their clinical service. Some severe asthma patients have inappropriate increases in corticosteroids in the absence of corticosteroid responsive inflammation, and this can lead to harmful side-effects. Our Consortium will validate a new way to optimise corticosteroid therapy using simple tests of corticosteroid response. We know that patients with low measures of certain asthma biomarkers have a low chance of having an asthma attack and we can safely reduce and optimise their corticosteroid treatment dose. This approach of corticosteroid treatment optimisation will identify two populations of severe asthma patients, with different patterns of lung inflammation, one with corticosteroid responsive disease which we call "T2-High"severe asthma and the other with corticosteroid unresponsive disease or "T2-Low" severe asthma. The T2-High group will be available for clinical trials of new treatments which have already been developed by the Pharmaceutical Industry. We currently understand much less about the T2-Low group, so these patients will be studied intensively to help us identify new drugs for this group. They will then be able to enter trials to test these new drugs. 
Type Management of Diseases and Conditions
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2015
Development Status Under active development/distribution
Clinical Trial? Yes
Impact Not applicable yet. 
URL http://www.rasp.org.uk
 
Title Service Evaluation of FeNO suppression test in severe asthma clinics 
Description Biomarker based assessment of adherence with inhaled steroids (FeNO suppression test) Non-adherence with inhaled corticosteroids (ICS) in poorly controlled severe asthma is common and consistently associated with poor clinical outcome. Adherence intervention studies using monitoring technologies and behavioural interventions have yielded mixed results but most studies have not aligned interventions with "biomarker based" assessment of therapeutic response to interpret clinical outcome. Poor adherence is a major stumbling block to improving asthma control and the development and validation of readily available protocol-driven adherence assessments would minimise the risk of committing patients with severe disease to inappropriate long-term expensive biological treatment. A number of novel biologic therapies targeting the Type-2 cytokine axis have shown efficacy in patients with severe asthma and payer organisations (e.g. the National Institute for Health and Care Excellence in the UK) provide guidance on access to these treatments. They are recommended as add-on therapies to optimised standard treatment including high dose ICS along with other controller medication, but no guidance is given on how to determine optimised standard therapy or adherence. Assessment of adherence to inhaled treatments can be challenging and physician estimate and patient self-report consistently overestimate adherence when compared to objective measures and other surrogate measures such as prescription records have limitations. Monitoring technologies remain the gold standard in clinical trials but clinical services have been slow to embrace these as part of routine care. We need to move away from trying to use challenging and imperfect surrogate measures of adherence to measuring the response to ICS using a responsive biomarker (fractional exhaled nitric oxide - FeNO). In patients with difficult to control severe asthma, this approach (FeNO suppression test) has previously been shown to identify "clinical non-adherence" when used with directly observed treatment over a seven day period. RASP-UK has now demonstrated that the FeNO suppression test can be delivered in routine clinical care and is straightforward to use for both the patient and the clinician. Profiling the FeNO response to ICS in patients with difficult to control severe asthma identifies a substantial population of patients who derive important clinical benefits from monitored ICS/LABA treatment. This approach also assists patients who wish to engage with a monitoring strategy in routine care and identifies patients who despite good adherence with inhaled treatment are likely to require additional treatment. Profiling the FeNO response to ICS exposure in patients with difficult to control severe asthma is a helpful part of clinical phenotyping and can usefully identify those who are likely to respond well to standard care with optimised treatment. In addition, aligning monitoring of ICS treatment with FeNO response will help exclude ICS responsive non-adherent subjects prior to recruitment to clinical trials investigating "add-on" interventions to standard care. This approach will also facilitate mechanistic studies investigating true ICS resistant disease. Future studies are required to identify the optimal intervention to maintain ongoing adherence in a difficult to control severe asthma population, but understanding the potential therapeutic benefit in an individual patient is an important component of routine assessment and clinical decision making. 
Type Diagnostic Tool - Non-Imaging
Year Development Stage Completed 2017
Development Status Under active development/distribution
Clinical Trial? Yes
Impact Manuscript under review. 
URL https://clinicaltrials.gov/show/NCT01219036
 
Title Somosa Study 
Description An open label, prospective, registration, multicentre study to identify biomarkers which are modulated by treatment with the anti-IgE antibody, Xolair. Objectives To improve understanding of the mechanisms of Xolair by assessing the effect of 16 weeks treatment with Xolair on urinary excretion of a key metabolite of prostaglandin 2 (PGD2), 2, 3-dinor-11-ß-PGF2a. To identify biomarkers which are predictive of a good clinical response, with the measurements of biomarkers being done after the first 16 weeks of treatment. Evaluate the value of using other clinical endpoints, either alone or in combination with measured biomarkers, to predict which participants treated with Xolair will benefit in terms of clinical improvement after 16 weeks of treatment and after 1 year of treatment. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2015
Development Status Under active development/distribution
Clinical Trial? Yes
Impact N/A at this stage 
URL http://www.southampton.ac.uk/ctu/trialportfolio/listoftrials/somosa
 
Description Asthma UK Press Release 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Inform stakeholders about the MRC funding announcement, the RASP UK research and potential impact for asthma patients.
Year(s) Of Engagement Activity 2015
URL https://www.asthma.org.uk/about/media/news/medical-research-council-mrc-asthma-uk-and-leading-pharma...
 
Description BTS 2017 Winter Meeting Presentation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Update in Asthma Treatment: Personalised Medicine Slide Presentation at the annual British Thoracic Society Winter Meeting December 2017
Year(s) Of Engagement Activity 2017
 
Description Global Respiratory Leadership Forum 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact 'Personalised dosing of inhaled steroids' presented to Global Respiratory Leadership Forum, Gothenburg, Sweden, 5th - 6th April 2019 Dr Garrett Greene
Year(s) Of Engagement Activity 2019
 
Description NICHE Email Campaign 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact NICHE email campaign circulating news stories, press releases and articles to approx 16,000 people.
Year(s) Of Engagement Activity 2015,2016,2017
 
Description RASP UK Newsletter 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Newsletter to regularly update study team members and professional practitioners on the progress of the study and invite articles from consortium members. Disseminates information to consortium members, industry bodies, patient input platform representatives and funding bodies.
Year(s) Of Engagement Activity 2015,2016,2017
URL http://www.rasp.org.uk
 
Description RASP UK Website 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact The website is one element of the dissemination and exploitation plan being used to direct project finding dissemination and build project awareness in anticipation of the reporting phase of the project maximizing its clinical exploitation potential. Its objective is to lay down the foundations for effective external communication of RASP-UK's concept and potential benefits to interested stakeholders at an international level, focusing primarily in the UK and Europe. The project will continue to take advantage of Asthma UK's media and press function, as well as its communication channels which reach many thousands of people with asthma.
Year(s) Of Engagement Activity 2015,2016,2017
URL http://www.rasp.org.uk
 
Description Stratified Medicine in Severe Asthma RASP UK Presentation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Slide presentation delivered by Professor Liam Heaney at Precision Medicine UK Collaboration Nation event. Leading figures in the research, development and commercialisation of precision medicine in the UK gathered at an event designed to encourage new partnerships and highlight new opportunities in the field.

The Precision Medicine UK: Collaboration Nation event at De Vere Holborn Bars, London, was organised by Innovate UK, Health and Care Research Wales, National Institute for Health Research, Cancer Research UK, Medical Research Council, Invest Northern Ireland and the Knowledge Transfer Network. It was part of a programme to make the UK a world leader in the field.
Year(s) Of Engagement Activity 2015
URL https://www.gov.uk/government/news/precision-medicine-uk-leaders-gather-to-discuss-new-treatments
 
Description Thoracic Society of Australia Keynote 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Keynote Speaker at Thoracic Society of Australia and New Zealand: Stratified Medicine in Severe Asthma - the RASP UK Consortium Programme 5th April 2016
Year(s) Of Engagement Activity 2006
 
Description World Asthma Day News Item 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Update on programme delivery and raise awareness of RASP UK whilst highlighting World Asthma Day. Also promoted on LinkedIn.
Year(s) Of Engagement Activity 2016
URL http://fyi-news.co.uk/rasp-uk-world-asthma-day-2016